Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 months ago

Possible Interaction: Debrisoquin and Quinidine

supplement:

Quinidine

Research Papers that Mention the Interaction

The extent to which quinidine altered these indices of encainide disposition was highly correlated with the metabolic ratio for debrisoquine oxidation (r = 0.62-0.95).
The Journal of pharmacology and experimental therapeutics  •  1989  |  View Paper
By pre-treatment with a typical CYP2D6 inhibitor, quinidine , the AUC0-8 value of 4-OH DB in High was decreased although such values in Low and uPA-/-/SCID mice did not change.
Journal of pharmaceutical sciences  •  2007  |  View Paper
Although both quinidine and quinine are competitive inhibitors of debrisoquine 4-hydroxylase activity in rat and man, their potency is reversed.
Quinidine is a potent inhibitor of debrisoquine 4-hydroxylase activity of human liver (IC50: 3.6 microM).
Biochemical pharmacology  •  1989  |  View Paper
However, two of them were on quinidine , a well known inhibitor of debrisoquine oxidation.
International Ophthalmology  •  2005  |  View Paper
In their study, they have also demonstrated that quinidine inhibits both CYP2D6- and CYP1A1-mediated debrisoquine 4-hydroxylation.
Drug metabolism and disposition: the biological fate of chemicals  •  2003  |  View Paper
Both the S(+)-4- and 7-hydroxylations of debrisoquine were inhibited by quinidine in both populations.
Pharmacogenetics  •  1993  |  View Paper
A single oral dose (50 mg) of quinidine significantly increased the debrisoquine metabolic ratio in six healthy volunteers.
It is concluded that quinidine , but not its diastereoisomer quinine, is a potent selective inhibitor of the in vivo oxidation of debrisoquine and can produce an artifactual PM phenocopy in persons who are phenotypically extensive metaboliser (EM) phenotype status.
Chirality  •  1991  |  View Paper
Biotransformation of substrates for the debrisoquine pathway can be markedly perturbed by even low doses of quinidine ; interindividual variability in drug interactions may have a genetic component.
British journal of clinical pharmacology  •  1989  |  View Paper
Quinidine was a potent inhibitor of the 4-hydroxylation of debrisoquine and the 1'-hydroxylation of bufuralol, with IC50 values of 0.7 and 0.2 microM, being around 100 times more potent in this respect than quinine.
British journal of clinical pharmacology  •  1986  |  View Paper